[one_full last=”yes” spacing=”yes” center_content=”no” hide_on_mobile=”no” background_color=”” background_image=”” background_repeat=”no-repeat” background_position=”left top” border_size=”0px” border_color=”” border_style=”” padding=”” margin_top=”” margin_bottom=”” animation_type=”” animation_direction=”” animation_speed=”0.1″ class=”” id=””][fusion_text]Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease
Brian Lipworth, Derek Skinner, Graham Devereux, Victoria Thomas, Joanna Ling Zhi Jie, Jessica Martin, Victoria Carter, David B Price
The first Cardio-vascular publication using data from OPCRD has just been published in ‘Heart’. The objective of the paper was to look at whether β-blockers are under used for patients with COPD suffering with heart failure.
In total it was found that only 22% of patients with Heart Failure and COPD were taking β-blockers and either ACEI/ARB, while that number was 41% if the patient only had Heart Failure.
This data indicated a substantial unmet need for patients with COPD who should be prescribed β-blockers more often for concomitant Heart Failure.
For the full article please click here.
ACM[/fusion_text][/one_full]
